Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis

NCT01824303 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

31

Enrollment

INDUSTRY

Sponsor class

Stopped This study was terminated early due to company decision.

Conditions

Interstitial Cystitis

Interventions

DRUG: LiRIS 400 mg
OTHER: LiRIS Placebo

Sponsor

Allergan

Collaborators

[object Object]